- Wednesday, June 25, 2025
Glenmark Pharmaceuticals has launched Tevimbra (tislelizumab) in India, a breakthrough immunotherapy for lung and esophageal cancers, marking its entry into the immuno-oncology space and offering patients access to a globally proven cancer treatment.
By: Vibhuti Pathak
Glenmark Pharmaceuticals has officially launched Tevimbra (tislelizumab), a novel lung cancer treatment, in India following approval from the Central Drugs Standard Control Organisation (CDSCO). This launch marks Glenmark’s first foray into the immuno-oncology segment in India, representing a significant milestone in expanding its innovative oncology portfolio.
Tevimbra is developed by BeiGene, now operating as BeOne Medicines, a global leader in oncology. The drug is a PD-1 monoclonal antibody designed to restore T-cell function and reduce immune suppression, providing a targeted immunotherapy option for difficult-to-treat cancers.
Indications and Treatment Scope
Tevimbra is indicated for:
Proven Global Efficacy and Safety
Tevimbra has been approved and marketed in over 46 countries, including major markets such as the United States, European Union, China, and Australia. It has been evaluated in 21 pivotal clinical trials involving nearly 14,000 patients worldwide and has been administered to more than 1.5 million patients globally.
The drug’s mechanism enhances immune response by blocking the PD-1 receptor, thereby enabling the body’s immune system to better detect and fight tumors. This targeted approach has shown strong efficacy and a favorable safety profile across multiple solid tumors.
Glenmark’s Commitment to Cancer Care
Alok Malik, President and Business Head – India Formulations at Glenmark Pharmaceuticals, highlighted the importance of this launch, “at a time when the cancer burden is rising sharply, we are proud to enable oncologists and patients to access Tevimbra, a therapy with proven efficacy and safety outcomes, strong science, and meaningful impact.”
He added, “Immuno-oncology offers a promising future for treating advanced cancers that are difficult to manage. Our entry into this space marks a significant inflection point in our journey to build a world-class oncology portfolio that is innovative, inclusive, and life-changing for patients.”
Strategic Impact and Future Outlook
With Tevimbra’s launch, Glenmark aims to strengthen its position in India’s oncology market by expanding access to next-generation immunotherapies. This move aligns with the company’s vision to address the growing cancer burden in India through advanced, research-driven treatment options.
The introduction of Tevimbra is expected to provide oncologists and patients with a globally benchmarked therapy, offering new hope for improved outcomes in lung and esophageal cancers. Glenmark’s partnership with BeiGene and its commitment to innovation signal a transformative phase in cancer care within the country.
